CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BERKELEY HEIGHTS, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the second quarter ended June 30, 2022, before the market open on Thursday, August 11, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

Thursday, August 11th @ 8:30am ET
Domestic: 1-877-423-9813
International: 1-201-689-8573
Conference ID: 13730940
Webcast: Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon the anticipated approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis if the NDA is approved, which will add an additional six months of marketing exclusivity once the study is completed. The company received a Complete Response Letter from FDA for the original NDA and we believe the deficiencies have been addressed in the resubmitted NDA that is under review by FDA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Staff

Recent Posts

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Conference Call and Webcast Scheduled for Tuesday August 12, 2025 at 4:30 PMWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus…

10 hours ago

GLOBO Language Solutions Honored as Silver Stevie® Award Winner for Technology Breakthrough of the Year − Artificial Intelligence

PHILADELPHIA, July 29, 2025 /PRNewswire/ -- GLOBO Language Solutions, the leading B2B provider of interpreting and…

10 hours ago

AI Just Got a Green Light from the White House–Here’s What That Means for Healthcare Stocks

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 29, 2025…

10 hours ago

Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report

ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the…

10 hours ago

Revolutionizing Patient Care Through Advanced Brain Monitoring and Generative AI

PHILADELPHIA, July 29, 2025 /PRNewswire/ -- In a bold step toward transforming neurocritical care, Moberg…

10 hours ago

PRC Enhances VoicesAI™ with Meta’s LLaMA to Deliver Predictive Comment Intelligence for Healthcare

Upgraded VoicesAI™ solution built with LLaMA—Meta's advanced open-source language model—delivers faster, smarter comment analysis and…

10 hours ago